Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Solute carrier family 22 member 15 (SLC22A15)
- Target
- SLC22A15
- Molecular classification
- Transporter, Solute carrier, Organic ion transporter, Zwitterion transporter
01
Overview
Solute carrier family 22 member 15 (SLC22A15) is a membrane transporter protein of the SLC22 family that mediates the transmembrane flux of various medically and physiologically important compounds—including zwitterionic and cationic metabolites, pharmaceuticals, toxins, hormones, and certain drugs. It bidirectionally transports molecules such as ergothioneine, carnitine (and acetylcarnitine), carnosine, betaine, thiamine, gabapentin, and cimetidine. SLC22A15 is most closely related to other zwitterion transporters like SLC22A4 and SLC22A5, but exhibits distinct substrate specificity. Its physiological and pharmacological roles are still being elucidated, with implications in metabolic regulation, drug response variability, and potential links to specific diseases such as carnitine deficiency and certain cancers. The gene encoding this protein is SLC22A15 and is also known by aliases such as FLIPT1 and PRO34686.
- Other names
- SLC22A15FLIPT1PRO34686solute carrier family 22 member 15
02
Mechanism of action
Substrate translocation (influx/efflux) across cell membranes by facilitated diffusion or sodium-dependent transport
03
Biological functions
Transmembrane transport of zwitterions, cations, amino acids and their derivativescellular uptake and efflux of metabolites and certain drugs
04
Disease associations
Carnitine deficiency, systemic primarypossible links to tumor growth and anti-asthmatic drug responseother roles under investigation
05
Safety considerations
Not currently establishedtransporter-related off-target effects or drug–drug interactions are possible, as with many solute carriers
06
Interacting drugs
Gabapentin
8 more in the full profile.
07
Biomarkers
Genetic polymorphisms in SLC22A15 have been associated with drug response (e.g., albuterol) and tumor growth, but specific biomarker status is not established
Beyond the preview
Go deeper on Solute carrier family 22 member 15 (SLC22A15).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solute carrier family 22 member 15 (SLC22A15).